Is gene silencing the future of Alzheimer’s disease treatment? Alnylam and Biogen presented first drafts of their answer to that question this week by publishing early-phase data on their respective RNAi and antisense approaches to treating the neurodegenerative disease. The two companies are using different technologies and pursuing different targets. Alnylam, through a partnership with […]
